Dearlove v. Genzyme Transgenics Corp.

70 Pa. D. & C.4th 314, 2004 Pa. Dist. & Cnty. Dec. LEXIS 308
CourtPennsylvania Court of Common Pleas, Philadelphia County
DecidedDecember 28, 2004
Docketno. 1031
StatusPublished
Cited by2 cases

This text of 70 Pa. D. & C.4th 314 (Dearlove v. Genzyme Transgenics Corp.) is published on Counsel Stack Legal Research, covering Pennsylvania Court of Common Pleas, Philadelphia County primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dearlove v. Genzyme Transgenics Corp., 70 Pa. D. & C.4th 314, 2004 Pa. Dist. & Cnty. Dec. LEXIS 308 (Pa. Super. Ct. 2004).

Opinion

SHEPPARD JR., J,

Plaintiffs have filed a motion for class certification. The court has considered this motion, defendant’s opposition to it, the respective briefs, counsel’s arguments presented at the certification hearing held on September 14, 2004, and all matters of record. For the reasons discussed, the court will issue a contemporaneous order granting the motion and certifying the case as a class action.

FINDINGS OF FACT

(1) Plaintiffs, George Dearlove and Annaregina Roberts, filed this putative class action alleging that GTC canceled the plaintiffs’ stock options, originally granted to them pursuant to GTC’s 1993 Equity Incentive Plan, in violation of the plan. Compl., ¶¶29-31.

(2) GTC is a biopharmaceuticals company with its headquarters and principal place of business at 175 Crossing Boulevard, Framingham, Massachusetts. Compl. ¶3.

(3) Previously, GTC owned a subsidiary called Pri-medica Corporation, also a biotechnology company with its headquarters and principal place of business in Worcester, Massachusetts. Compl., ¶5. GTC also previously owned Primedica’s five subsidiaries: Primedica Worcester Inc., Primedica Cambridge Inc., Primedica Argus Research Laboratories Inc., Primedica Redfield [317]*317Inc., and Primedica Rockville Inc. Compl., ¶4. (Primedica Corporation and its subsidiaries will be referred to in this opinion, collectively, as Primedica.)

(4) At all relevant times, plaintiffs have been employed by Primedica Argus Research Laboratories Inc. Compl., ¶4; def’s motion for summary judgment, p. 9. In February 1996, Mr. Dearlove entered into a severance agreement with GTC, Primedica’s parent corporation at the time. Def’s motion, Green aff, exhibit 8.

(5) In 1993, GTC instituted an incentive stock option plan entitled the 1993 Equity Incentive Plan to award stock options to employees of GTC and its affiliates. Compl., ¶¶6, 9.

(6) The plan stated that its purpose was to “attract and retain key employees and consultants to provide an incentive for them to assist [GTC] to achieve long-range performance goals, and to enable them to participate in the long-term growth of [GTC].” Pltfs’ response to def’s motion for summary judgment, exhibit 2, §1.

(7) The plan defined “affiliate” to mean any business entity in which GTC owned directly or indirectly 50 percent or more of the total combined voting power or had a significant financial interest as determined by the committee which comprised GTC’s Board of Directors or members of that board. Pltfs’ response, exhibit 2, §2. Under this definition, affiliates included Primedica, and therefore, GTC awarded stock options pursuant to the plan to employees of Primedica, including plaintiffs.

(8) During the period from 1993 until 2000, GTC issued stock options to George Dearlove eight times, in different amounts and at varying prices per share. Compl., ¶6 and exhibits A, B (Notice of grant of stock options and option agreement, reflecting some stock options [318]*318which would expire on May 19,2005 and some of which would expire on May 24,2010); def’s motion, p. 10 and Nagle aff, exhibit 1; pltfs’ response, exhibit 20. During the same period of time, GTC issued stock options to Annaregina Roberts seven times, in different amounts and at varying prices per share. Compl., ¶6; def’s motion, p. 10 and Nagle aff, exhibit 1; pltfs’ response, exhibit 21. GTC gave plaintiffs several documents each time it issued plaintiffs stock options, including a notice of grant of stock options and option agreement, the plan prospectus, and incentive stock option terms and conditions (also known as the reverse side of the “incentive stock option certificate” or “award agreement.” Compl., ¶¶7-8 and exhibit C, p. 5; pltfs’ response, exhibits 20, 21; def’s motion, p. 10.

(9) On February 6, 2001, GTC entered into a stock purchase agreement with Charles River Laboratories International Inc. to sell all of the capital stock of Primedica.1 The closing of the sale occurred on February 26, 2001. Def’s motion, p, 9.

(10) According to the parties’ joint stipulation, on March 30, 2001, Charles River merged all of the Pri-medica subsidiaries into Primedica, and then merged Primedica into Charles River. Def’s opposition to class certification, exhibit 1, ¶4.

(11) GTC states that it has never had any corporate affiliation with Charles River. Def’s motion, p. 9.

[319]*319(12) Significantly for plaintiffs, the stock purchase agreement states that all options issued by GTC to optionees, other than to certain identified individuals holding management positions, would terminate according to the terms of the options. Def’s motion, Green aff., exhibit 1.

(13) On March 9,2001, GTC contends that it notified Primedica employees who held stock options that they had until May 26,2001 to exercise their options that were vested as of February 26, 2001, the date that the sale of Primedica to Charles River closed. Def’s motion, Nagle aff., exhibit 4. Plaintiffs dispute that GTC gave such notice to any Primedica employee from Pennsylvania.

(14) In any event, stock options held by Primedica employees which were not exercised by May 26, 2001, were canceled by GTC. Compl., ¶31. Specifically, if an optionee held a stock option that was vested as of February 26,2001, and the optionee did not exercise it by May 26,2001, GTC canceled that option. If an optionee held a stock option that was unvested as of February 26,2001, GTC determined that the option could not be exercised and canceled it. Def’s motion, p. 11. On May 26, 2001, GTC canceled stock options held by plaintiffs. Def’s motion, pp. 12-13; see also, def’s motion, Nagle aff., exhibit 6.

(15) On November 13, 2001, Dearlove and Roberts filed the complaint on behalf of a putative class. Compl., ¶13.

(16) In their motion for class certification, the plaintiffs define the “class” as: “All employees of Primedica Corporation and it[s] subsidiaries who, as of February 7, 2001, had been awarded stock options and who had not yet exercised their options, excluding members of the [320]*320Primedica management team.” Pltf’s motion for class certification, p. 1.

(17) The parties contend that the “putative class comprises approximately 625 persons who were employees of Primedica Corporation and its subsidiaries as of February 7, 2001 (the date on which GTC announced its sale of Primedica Corporation and its subsidiaries to Charles River Labs), and who, as of that date, had unex-ercised employee stock options in GTC.” Joint stipulation, ¶1. The parties further contend that the “putative class does not include Peter Glick and the six members of the Primedica Corporation management team as of February 26, 2001 (the date on which GTC sold Pri-medica to Charles River Labs), whose options were treated differently from the putative class members in connection with the divestiture of Primedica.” Joint stipulation, ¶1.

(18) The complaint alleges three counts against defendant GTC: breach of contract, breach of covenant of good faith and fair dealing, and unjust enrichment. Compl., ¶¶28-36, 37-42, 43-47.

(19) On September 14, 2004, this court held a class certification hearing pursuant to Rule 1707 of the Pennsylvania Rules of Civil Procedure.

DISCUSSION

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Roverano, W. v. John Crane, Inc.
177 A.3d 892 (Superior Court of Pennsylvania, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
70 Pa. D. & C.4th 314, 2004 Pa. Dist. & Cnty. Dec. LEXIS 308, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dearlove-v-genzyme-transgenics-corp-pactcomplphilad-2004.